Salvacyl: new treatment for male sexual deviation

Salvacyl (triptorelin) is a new long-acting treatment for men with severe sexual deviations.

It is administered every 12 weeks as a single 11.25mg intramuscular injection.

Triptorelin is a GnRH agonist. It lessens sexual drive by inhibiting secretion of LH and FSH, thereby reducing testosterone production. Other preparations of triptorelin are used to treat precocious puberty, endometriosis and prostate cancer.

Treatment with Salvacyl should be initiated and monitored by a psychiatrist, and must be given in combination with psychotherapy.

View Salvacyl drug record

Further information: Ipsen

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Elleste Duet, Elleste Solo, Diprosone and Livial.

Potentially addictive medicines 'being prescribed for years'

Potentially addictive medicines 'being prescribed for years'

Hundreds of thousands of people are receiving prescriptions...